Improving Outcomes in Patients with Gastric Cancer with Optimal Use of Guideline-recommended First- and Second-line Therapies and a Multidisciplinary Team Approach

In this MediTalkTM activity, the expert faculty will review the safety, efficacy, and mechanisms of action of currently available and emerging targeted agents in addition to systemic therapies. The faculty will review the current evidence on adjuvant therapies and will highlight the importance of a multidisciplinary approach. More importantly, the faculty will provide strategies for incorporating the currently available targeted agents in the first- or second-line setting in managing patients with gastric cancer (GC) and improving their overall outcomes.

Target Audience

This activity is designed for medical oncologists, radiation oncologists, and other healthcare professionals interested in managing patients with GC.

Educational Objectives

Upon completion of this activity, participants will be able to:

  1. Manage patients with resectable GC appropriately with adjuvant therapies using a multidisciplinary approach.
  2. Use systemic therapies and targeted therapies in the first- or second-line setting appropriately in managing patients with GC.
  3. Evaluate the mechanisms of action, safety, and efficacy of currently available and emerging targeted GC therapies.

Faculty

 

Charles S. Fuchs, MD, MPH, FACP
Chief, Division of Gastrointestinal Oncology
Dana-Farber Cancer Institute
Robert T. and Judith B. Hale Chair
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

 

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

Charles S. Fuchs, MD, MPH, FACP

Consultant/Advisor: Amgen, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; MedImmune, Inc.; Merck & Co., Inc.; Pfizer, Inc.; sanofi-aventis

Non-Faculty: Tara Frate; Sara Sloan; Sandy Breslow; Bernard Abrams, MD; and Alison Kemp hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Janardhan Sampath, PhD, hereby states that his spouse/life partner is employed by Amgen, Inc. 

Financial Support

This activity has been supported by an independent educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and ACCELMED. 

           

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ACCELMED, and Lilly do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician
Course opens: 
12/30/2015
Course expires: 
12/29/2016
Rating: 
3

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician

Accreditation Period

Course opens: 
12/30/2015
Course expires: 
12/29/2016
Please login or register to take this course.